We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$43.6B
AUM Growth
-$9.03B
(-17%)
Cap. Flow
-$1.48B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
21.41%
Holding
1,190
New
110
Increased
278
Reduced
409
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$364M |
| 2 |
SIVB
SVB Financial Group
SIVB
|
+$155M |
| 3 |
Textron
TXT
|
+$103M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$102M |
| 5 |
Sanofi
SNY
|
+$96.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$333M |
| 2 |
ExxonMobil
XOM
|
+$242M |
| 3 |
Dollar Tree
DLTR
|
+$231M |
| 4 |
Nutrien
NTR
|
+$213M |
| 5 |
National Vision
EYE
|
+$198M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.53% |
| 2 | Healthcare | 17.73% |
| 3 | Financials | 14.85% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Dyne Therapeutics
DYN
$4.71B
| $3.92M | 0.01% |
570,000
-180,000
| -24% | -$1.24M |
|
827
Kimbell Royalty Partners
KRP
$1.46B
| $3.87M | 0.01% |
246,667
-1,753,333
| -88% | -$30.5M |
|
828
Amylyx Pharmaceuticals
AMLX
$2.24B
| $3.85M | 0.01% |
200,000
+162,800
| +438% | +$1.93M |
|
829
WillScot Mobile Mini Holdings
WSC
$4.66B
| $3.85M | 0.01% |
118,768
-380,072
| -76% | -$13.5M |
|
830
American Homes 4 Rent
AMH
$12.4B
| $3.75M | 0.01% |
+105,943
| New | +$4.01M |
|
|
NMTR
831
DELISTED
9 Meters Biopharma
NMTR
| $3.73M | 0.01% |
714,781
-35,219
| -5% | -$332K |
|
832
CytomX Therapeutics
CTMX
$690M
| $3.66M | 0.01% |
2,000,000
| – | – |
|
833
Annexon
ANNX
$860M
| $3.6M | 0.01% |
955,630
-4,200
| -0.4% | -$12.8K |
|
|
PRVB
834
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $3.6M | 0.01% |
900,000
+190,677
| +27% | +$904K |
|
|
ETNB
835
DELISTED
89bio
ETNB
| $3.54M | 0.01% |
+1,100,000
| New | +$3.32M |
|
836
Generac Holdings
GNRC
$11.9B
| $3.47M | 0.01% |
16,458
-49,400
| -75% | -$12.1M |
|
|
SAFM
837
DELISTED
Sanderson Farms Inc
SAFM
| $3.46M | 0.01% |
16,050
-89,732
| -85% | -$17.6M |
|
|
PACX
838
DELISTED
Pioneer Merger Corp. Class A Ordinary Share
PACX
| $3.45M | 0.01% |
350,000
| – | – |
|
839
TotalEnergies
TTE
$193B
| $3.42M | 0.01% |
65,000
+30,000
| +86% | +$1.6M |
|
840
TaskUs
TASK
$582M
| $3.41M | 0.01% |
202,357
-212,643
| -51% | -$5.42M |
|
841
Henry Schein
HSIC
$9.85B
| $3.36M | 0.01% |
43,800
-101,000
| -70% | -$8.47M |
|
|
ARIS
842
DELISTED
Aris Water Solutions
ARIS
| $3.34M | 0.01% |
+200,000
| New | +$3.63M |
|
843
Newell Brands
NWL
$2.71B
| $3.3M | 0.01% |
173,300
-230,100
| -57% | -$4.89M |
|
|
EPIX
844
DELISTED
ESSA Pharma
EPIX
| $3.28M | 0.01% |
1,042,531
-500,000
| -32% | -$2.79M |
|
845
Brunswick
BC
$5.16B
| $3.27M | 0.01% |
50,000
-75,000
| -60% | -$5.51M |
|
|
NEX
846
DELISTED
NexTier Oilfield Solutions Inc.
NEX
| $3.23M | 0.01% |
340,000
-110,000
| -24% | -$1.15M |
|
847
Rapid Micro Biosystems
RPID
$106M
| $3.23M | 0.01% |
750,000
+50,000
| +7% | +$233K |
|
848
Cactus
WHD
$5.12B
| $3.22M | 0.01% |
80,000
| – | – |
|
849
Fox Class A
FOXA
$24.6B
| $3.2M | 0.01% |
99,619
-230,200
| -70% | -$8.1M |
|
850
United Airlines
UAL
$41.7B
| $3.2M | 0.01% |
90,309
+2,200
| +2% | +$96.6K |
|
Similar funds
Adage Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Adage Capital Partners held 1,190 positions worth $43.6B, down 17% from $52.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.48B in Q2 2022, closing 115 positions and reducing 409 holdings. Its most notable exit was Nutrien, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Booz Allen Hamilton worth $75.6M.
- Adage Capital Partners's largest Q2 2022 buy was Booz Allen Hamilton: 837,064 shares worth $75.6M.
- Adage Capital Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, an estimated $364M increase.
- Adage Capital Partners's biggest Q2 2022 reduction was Royalty Pharma, cutting an estimated $333M.
- Adage Capital Partners fully exited Nutrien in Q2 2022, selling an estimated $213M.
- Adage Capital Partners's ten largest holdings make up 21% of its $43.6B portfolio in Q2 2022.
- Adage Capital Partners opened 110 new positions and closed 115 in Q2 2022.
- Adage Capital Partners's portfolio value fell 17% quarter-over-quarter to $43.6B.
Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.